MS
SRNE

Maven Securities’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Maven Securities’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,800
Closed -$15K – 1446
2021
Q1 		$15K Buy
+1,800
New +$19K ﹤0.01% 1146

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Maven Securities's SRNE Position: Q2 2021 in Review

Maven Securities sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2021, closing a stake of 1,800 shares — an estimated $15K sold.

Maven Securities first reported a position in SRNE in Q1 2021 and held it in 1 quarter. The position peaked at $15K in Q1 2021. 212 funds tracked by Wall St. Rank hold SRNE as of Q2 2021.

  • Maven Securities reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 1,800 Sorrento Therapeutics, Inc. shares in Q2 2021, an estimated $15K.
  • Maven Securities first reported a position in Sorrento Therapeutics, Inc. in Q1 2021 and held it in 1 quarter.
  • Maven Securities's Sorrento Therapeutics, Inc. position peaked at $15K in Q1 2021.
  • 212 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.